Merck (MRK) Dividends payables (2009 - 2026)
Merck (MRK) posted quarterly Dividends payables of $2.1 billion for Q1 2026, up 3.18% year-over-year from $2.1 billion in Q1 2025, and little changed quarter-over-quarter from $2.1 billion in Q4 2025.
Merck (MRK) Dividends payables (2009 - 2026) Analysis & Trends
Merck (MRK) has reported Dividends payables for 18 consecutive years, with $2.1 billion the latest figure, recorded in Q1 2026.
- In Q1 2026, Dividends payables rose 3.18% year-over-year to $2.1 billion; the TTM figure through Mar 2026 stood at $2.1 billion (up 3.18% YoY), while the FY2025 annual figure was $2.1 billion, up 2.69% from the prior year.
- Dividends payables held at $2.1 billion in Q1 2026 per MRK's latest filing, from $2.1 billion in the prior quarter.
- Across five years, Dividends payables topped out at $2.1 billion in Q1 2026 and bottomed at $1.8 billion in Q2 2022.
- Historically, Dividends payables has averaged $2.0 billion across 5 years, with a median of $2.0 billion in 2024.
- Annual changes were most pronounced in 2023 — Dividends payables advanced 7.68% — and 2025, when it increased 2.69%.
- Merck's Dividends payables stood at $1.9 billion in 2022, then rose by 5.36% to $2.0 billion in 2023, then increased by 4.99% to $2.1 billion in 2024, then increased by 2.69% to $2.1 billion in 2025, then gained by 0.14% to $2.1 billion in 2026.
- Business Quant data shows MRK's Dividends payables at $2.1 billion in Q1 2026, $2.1 billion in Q4 2025, and $2.0 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Dividends payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.88 Bn | 625.12 Bn | 17.26 Bn | - |
| 2 | AbbVie | 463.46 Bn | 456.89 Bn | 12.70 Bn | - |
| 3 | Merck | 367.92 Bn | 360.78 Bn | 12.21 Bn | 2.13 Bn |
| 4 | Novartis Ag | 297.71 Bn | 290.02 Bn | 11.24 Bn | - |
| 5 | Astrazeneca | 255.55 Bn | 250.65 Bn | 12.86 Bn | - |
| 6 | Amgen | 234.52 Bn | 220.53 Bn | 7.24 Bn | - |
| 7 | Gilead Sciences | 178.22 Bn | 175.04 Bn | 6.22 Bn | - |
| 8 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | 2.45 Bn |
| 9 | Gsk | 105.32 Bn | 101.15 Bn | 8.24 Bn | - |
| 10 | Sanofi | 54.20 Bn | 46.82 Bn | 10.79 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.13 Bn |
| Mar 31, 2026 | 2.14 Bn |
| Dec 31, 2025 | 2.14 Bn |
| Sep 30, 2025 | 2.04 Bn |
| Jun 30, 2025 | 2.05 Bn |
| Mar 31, 2025 | 2.08 Bn |
| Dec 31, 2024 | 2.08 Bn |
| Sep 30, 2024 | 1.98 Bn |
| Jun 30, 2024 | 1.98 Bn |
| Mar 31, 2024 | 2.01 Bn |
| Dec 31, 2023 | 1.99 Bn |
| Sep 30, 2023 | 1.88 Bn |
| Jun 30, 2023 | 1.88 Bn |
| Mar 31, 2023 | 1.91 Bn |
| Dec 31, 2022 | 1.88 Bn |
| Sep 30, 2022 | 1.77 Bn |
| Jun 30, 2022 | 1.77 Bn |
| Mar 31, 2022 | 1.77 Bn |
| Dec 31, 2021 | 1.77 Bn |
| Sep 30, 2021 | 1.66 Bn |